ZTS — animal health at 12x earnings

Zoetis (NYSE: ZTS) is this week's featured stock. Zoetis is an animal-health company spun out of Pfizer in 2013; its business sells medicines, vaccines, diagnostics, and related products for companion animals and livestock. The stock closed near $74.80 in early July 2026, with a market cap of about $31.36B, a 12.25x trailing P/E, $2.24B in TTM free cash flow, and a 7.13% FCF yield. 1

ZTS clears the channel's three hard gates, but this is not a clean momentum story. The attraction is that a still-profitable animal-health leader now trades at the lowest P/E multiple in its public history. 2 The caution is that the stock is cheap because investors are questioning U.S. companion-animal demand, Elanco competition, Librela safety concerns, and management's credibility after a guidance cut. 34

Zoetis uses a calendar fiscal year ending December 31. In this article, FY2025 means the fiscal year ended December 31, 2025, and TTM refers to the latest trailing-twelve-month period available in the cited source. 5

The ROE gate is easy to verify and hard to use naively. ZTS has stayed far above the 15% hurdle for each of the last three fiscal years, with FY2023 at 49.82%, FY2024 at 51.14%, and FY2025 at 65.99%. 6 The issue is quality of the denominator: Zoetis bought back $1.09B of stock in FY2023, $1.86B in FY2024, and $3.24B in FY2025, which pushed book equity lower and lifted ROE. 7

That is why ROIC matters here. StockAnalysis shows Zoetis with 27.80% TTM ROIC, which still points to a high-return business even after stripping out the most obvious buyback distortion. 6

The free-cash-flow gate is cleaner. Zoetis generated $1.62B of FCF in FY2023, $2.30B in FY2024, $2.28B in FY2025, and $2.14B TTM through March 2026. 7 The statistics page shows $2.24B of TTM FCF and a 7.13% FCF yield at the current market cap, so the cash-flow screen passes even using the lower of the two TTM FCF figures. 1

Zoetis is a large animal-health company. Its portfolio spans companion-animal drugs such as Apoquel, Cytopoint, Simparica Trio, Librela, and Solensia, plus livestock products used in cattle, swine, poultry, fish, and sheep. Morningstar maintained a Wide Moat rating in May 2026 and described Zoetis as "the undisputed leader in the global animal health industry" with "the widest moat of all the competitors." 8

The income statement still looks strong. Revenue rose from $8.54B in FY2023 to $9.26B in FY2024 and $9.47B in FY2025, while TTM revenue reached $9.51B. 5 Net income rose from $2.34B in FY2023 to $2.50B in FY2024 and $2.67B in FY2025, with TTM net income at $2.64B. 5

Margins also support the quality case. Zoetis posted operating margins of 35.3% in FY2023, 36.1% in FY2024, 37.5% in FY2025, and 36.8% TTM. 5 Net margin stayed near the high-20s, moving from 27.4% in FY2023 to 27.0% in FY2024, 28.2% in FY2025, and 27.8% TTM. 5

The balance sheet is the weak spot in the quality picture. Total debt rose from $6.76B in FY2023 to $9.24B in FY2025, while book equity fell from $5.00B to $3.33B. 9 The D/E ratio now sits at 2.86, but interest coverage of 15.80x and a current ratio of 3.15 suggest that debt service and short-term liquidity are not immediate stress points. 6

The dividend adds a shareholder-return floor, although it is not the main thesis. Zoetis pays $2.12 per share annually, equal to a 2.83% yield, with a 34.22% payout ratio and 12 consecutive years of dividend growth. 1

The valuation case is unusually stark. Zoetis traded at annual P/E multiples of 57.15x in FY2021, 32.64x in FY2022, 38.93x in FY2023, 29.79x in FY2024, and 20.90x in FY2025; the current 12.25x trailing P/E is far below that five-year range. 6 Macrotrends shows a current P/E near 11.56x, below the prior public-company peaks of 64.59x in 2015 and 54.47x in 2021. 2

The peer comparison also favors ZTS on earnings and cash-flow multiples. IDEXX Laboratories (NASDAQ: IDXX), a veterinary diagnostics leader, trades at 41.03x trailing earnings, 29.05x EV/EBITDA, and 40.61x P/FCF. 10 Elanco Animal Health (NYSE: ELAN), Zoetis's closest pure-play animal-health competitor, has negative TTM earnings and trades at 16.86x EV/EBITDA and 39.64x P/FCF. 11

This is enough for the valuation gate, but it does not mean the stock is risk-free. ZTS is cheaper than IDXX and ELAN because its growth outlook has been hit directly. Revenue growth slowed from 8.33% in FY2024 to 2.28% in FY2025, and TTM revenue growth was 2.65%. 5 A low P/E becomes compelling only if earnings stop being revised down.

The first risk is the May 2026 earnings break. Zoetis reported Q1 2026 revenue of $2.26B, below the $2.30B consensus estimate, and adjusted EPS of $1.53, below the $1.60 consensus estimate. 3 The company cut FY2026 revenue guidance to $9.68B-$9.96B and adjusted EPS guidance to $6.85-$7.00, and the stock fell about 21.5% in one session. 3

Management's explanation matters because it points to demand and competition rather than a one-off accounting issue. CEO Kristin Peck said pet owners showed "increased price sensitivity," which led to fewer veterinary visits and softer demand for premium products; she also said competition intensified in dermatology and parasiticides. 3 Those are exactly the categories where Zoetis has relied on high-value companion-animal franchises.

The second risk is product concentration. Scuttleblurb reported that Simparica and Apoquel are $1B+ franchises representing 16% and 12% of Zoetis's 2025 revenue, respectively, and that the two products together accounted for about 54% of the company's incremental top-line growth since 2013. 12 If Elanco's Zenrelia pressures Apoquel and Cytopoint in dermatology, and Credelio Quattro pressures Simparica Trio in parasiticides, the headwind hits the products that have mattered most to the growth algorithm. 4

The third risk is Librela. A securities class action against Zoetis, CEO Kristin Peck, and CFO Wetteny Joseph covers the period from January 14, 2025 through May 6, 2026 and alleges that management misrepresented the strength and durability of flagship companion-animal products. 4 The same filing points to FDA safety warnings around Librela and lists a July 27, 2026 lead plaintiff deadline. 4 The legal filing is an allegation, not a proven finding, but it is still a live overhang for the stock.

Insider activity is mixed. CEO Kristin Peck sold 20,000 shares at roughly $127 on February 17, 2026, for about $2.54M, and recent C-suite activity has not included open-market buying. 13 The offset is that three non-executive directors bought shares after the crash, including Michael McCallister's 3,000 shares at $77.76 on May 11, 2026, and InsiderScreener shows $886,367 of net insider buying over the last 90 days. 13

Analysts are also split. Yahoo Finance coverage reported that Stifel saw near-term competitive pressure as likely to intensify, while Argus downgraded ZTS from Buy to Hold after the stock's collapse. 14 Finviz shows a Buy consensus and an average price target near $109.71, while Barclays cut its target to $85 from $136 in early July. 15

The next scheduled catalyst is Q2 2026 earnings on August 6, 2026, before the market opens. 16 That report should be judged on four items: whether U.S. Companion Animal revenue stabilizes, whether management confirms or cuts the $9.68B-$9.96B revenue guidance range, whether FCF stays near the $2.1B-$2.2B TTM run rate, and whether commentary on Apoquel, Cytopoint, Simparica Trio, Librela, and Solensia gets better or worse. 37

The dividend date is nearer but less important. Zoetis's next ex-dividend date is July 20, 2026, and the quarterly dividend is $0.53 per share. 16 The dividend yield helps while investors wait, but the stock will not rerate unless the company shows that the companion-animal franchise is not deteriorating further.

The bottom line: ZTS is this week's qualified pick because the three hard criteria are all numerically verifiable. The company has three-year ROE far above 15%, positive FCF in every year reviewed, and a valuation that is low versus its own public history and the two most relevant animal-health peers. 167 The decision for investors is whether a 12.25x P/E and 7.13% FCF yield are enough compensation for slower growth, higher leverage, Elanco pressure, and the Librela/legal overhang. 14